浏览全部资源
扫码关注微信
1.北京医院药学部/国家老年医学中心/中国医学科学院老年医学研究院/北京市药物临床风险与个体化应用评价重点实验室(北京医院),北京 100730
2.中央军委联合参谋部警卫局卫生保健处,北京 100173
Published:15 November 2024,
Received:04 May 2024,
Revised:07 September 2024,
移动端阅览
郑子恢,赵紫楠,高峰等.乌司他丁治疗急性胰腺炎的快速卫生技术评估 Δ[J].中国药房,2024,35(21):2676-2683.
ZHENG Zihui,ZHAO Zinan,GAO Feng,et al.Rapid health technology assessment of ulinastatin in the treatment of acute pancreatitis[J].ZHONGGUO YAOFANG,2024,35(21):2676-2683.
郑子恢,赵紫楠,高峰等.乌司他丁治疗急性胰腺炎的快速卫生技术评估 Δ[J].中国药房,2024,35(21):2676-2683. DOI: 10.6039/j.issn.1001-0408.2024.21.17.
ZHENG Zihui,ZHAO Zinan,GAO Feng,et al.Rapid health technology assessment of ulinastatin in the treatment of acute pancreatitis[J].ZHONGGUO YAOFANG,2024,35(21):2676-2683. DOI: 10.6039/j.issn.1001-0408.2024.21.17.
目的
2
本文通过对乌司他丁(UTI)进行快速卫生技术评估(HTA),评价UTI治疗急性胰腺炎(AP)的有效性、安全性及经济性。
方法
2
计算机检索PubMed、Embase、the Cochrane Library、中国知网、万方数据库、中国生物医学文献数据库和HTA机构官方网站,收集UTI在AP方面的系统评价(SR)/Meta分析、经济学评价及HTA报告,检索时限为建库至2024年4月。由2名研究者根据纳排标准独立进行筛选、质量评价和数据提取,采取描述性分析方式对数据进行分析汇总。
结果
2
共纳入19篇研究,包括15篇SR/Meta分析和4篇经济学研究,未检索到HTA报告。UTI联合治疗AP较单独常规治疗在提高总有效率、缩短淀粉酶恢复时间、减少腹痛腹胀缓解时间、降低病死率及缩短平均住院天数等方面均具有明显优势,和其他阳性药物(甲磺酸加贝酯、奥曲肽、生长抑素)相比疗效相当或基本一致,安全性良好。就目前纳入的研究而言,UTI对比其他阳性药物具有明显经济学优势。
结论
2
UTI在治疗AP方面安全有效,具有经济学优势。
OBJECTIVE
2
To conduct rapid health technology assessment (HTA) of ulinastatin (UTI), and to evaluate the efficacy, safety and cost-effectiveness of UTI in the treatment of acute pancreatitis (AP).
METHODS
2
Retrieved from PubMed, Embase, the Cochrane Library, CNKI, Wanfang database, CBM and official websites of HTA institutions, the systematic review (SR)/meta-analysis, economic evaluation and HTA reports of UTI in the treatment of AP were collected from the inception to Apr. 2024. Two researchers independently conducted screening, quality evaluation and data extraction according to the admission and exclusion criteria, and descriptive analysis was adopted to analyze and summarize the data.
RESULTS
2
A total of 19 studies were included, involving 15 SR/meta-analysis and 4 economic studies, and no HTA report was retrieved. In the treatment of AP, UTI showed clear advantages over conventional treatment alone in terms of improving the overall effective rate, shortening the recovery time of amylase, reducing the time required to relieve abdominal pain and distension, lowering the mortality rate, and decreasing the average hospital stay. Compared to other positive drugs (carbendate mesylate, octreotide, somatostatin, etc.), its efficacy is similar, with a favorable safety profile. As far as the current research was concerned, UTI had obvious economic advantages over other positive drugs.
CONCLUSIONS
2
UTI is safe and effective in the treatment of AP, and has economic advantages.
乌司他丁急性胰腺炎有效性安全性经济性快速卫生技术评估循证学评价
acute pancreatitisefficacysafetycost-effectivenessrapid health technology assessmentevidence-based evaluation
YADAV D,LOWENFELS A B. The epidemiology of pancreatitis and pancreatic cancer[J]. Gastroenterology,2013,144(6):1252-1261.
VAN DIJK S M,HALLENSLEBEN N D L,VAN SANTVOORT H C,et al. Acute pancreatitis:recent advances through randomised trials[J]. Gut,2017,66(11):2024-2032.
杜奕奇,陈其奎,李宏宇,等. 中国急性胰腺炎诊治指南(2019年,沈阳)[J]. 临床肝胆病杂志,2019,35(12):2706-2711.
DU Y Q,CHEN Q K,LI H Y,et al. Chinese guidelines for the management of acute pancreatitis(Shenyang,2019)[J]. J Clin Hepatol,2019,35(12):2706-2711.
孙洋,张波,武琼. 乌司他丁治疗急性胰腺炎对患者免疫功能及炎症介质水平的影响[J]. 海南医学,2023,34(24):3540-3543.
SUN Y,ZHANG B,WU Q. Effects of ulinastatin on immune function and levels of inflammatory mediators in patients with acute pancreatitis[J]. Hainan Med J,2023,34(24):3540-3543.
马道安,刘平,李坤,等. 乌司他丁联合奥曲肽用于急性胰腺炎患者的疗效及安全性观察[J]. 大医生,2024,9 (1):1-3.
MA D A,LIU P,LI K,et al. Observation of the efficacy and safety of combination therapy of ulinastatin and octreotide in patients with acute pancreatitis.[J]. Doctor,2024,9 (1):1-3.
侯君,郑喜胜,李长力. 乌司他丁联合生长抑素治疗急诊重症急性胰腺炎的疗效观察[J]. 深圳中西医结合杂志,2024,34(5):98-101.
HOU J,ZHENG X S,LI C L. Clinical observation of ulinastatin combined with somatostatin in the treatment of emergency severe acute pancreatitis[J]. Shenzhen J Integr Tradit Chin West Med,2024,34(5):98-101.
陈超. 加贝酯联合乌司他丁对急性胰腺炎患者临床症状改善及炎症指标的影响[J]. 中国药物经济学,2023,18(8):46-49,53.
CHEN C. Effect of gabexate combined with ulinastatin on improvement of clinical symptoms and inflammatory indexes in patients with acute pancreatitis[J]. China J Pharm Econ,2023,18(8):46-49,53.
李幼平,喻佳洁,孙鑫. 快速评估方法与流程的探索[J]. 中国循证医学杂志,2014,14(5):497-500.
LI Y P,YU J J,SUN X. Exploring the method and process of rapid review[J]. Chin J Evid Based Med,2014,14(5):497-500.
刘梦娜,吴斌,艾丹丹,等. 药物快速卫生技术评估方法学研究:以抗肿瘤用药为例[J]. 中国药房,2022,33(11):1386-1391.
LIU M N,WU B,AI D D,et al. Methodological study of rapid health technology assessment of drugs:taking antitumor drugs as an example[J]. China Pharm,2022,33(11):1386-1391.
唐惠林,门鹏,翟所迪. 药物快速卫生技术评估方法及应用[J]. 临床药物治疗杂志,2016,14(2):1-4.
TANG H L,MEN P,ZHAI S D. Introducing and explo- ring the method of rapid review on drugs[J]. Clin Med J,2016,14(2):1-4.
葛龙,潘蓓,潘佳雪,等. 解读AMSTAR-2:基于随机和(或)非随机对照试验系统评价的质量评价工具[J]. 中国药物评价,2017,34(5):334-338.
GE L,PAN B,PAN J X,et al. An introduction of AMSTAR-2:a quality assessment instrument of syste- matic reviews including randomized or non-randomized controlled trials or both[J]. Chin J Drug Eval,2017,34(5):334-338.
HUSEREAU D,DRUMMOND M,PETROU S,et al. Consolidated health economic evaluation reporting standards (CHEERS) statement[J]. Value Health,2013,16(2):e1-5.
HAILEY D. Toward transparency in health technology assessment:a checklist for HTA reports[J]. Int J Technol Assess Health Care,2003,19(1):1-7.
HORVÁTH I L,BUNDUC S,FEHÉRVÁRI P,et al. The combination of ulinastatin and somatostatin reduces complication rates in acute pancreatitis:a systematic review and meta-analysis of randomized controlled trials[J]. Sci Rep,2022,12(1):17979.
WANG L Z,LUO M Y,ZHANG J S,et al. Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment:a meta-analysis[J]. Int J Clin Pharmacol Ther,2016,54(11):890-898.
ZHANG C Z,WANG Y J,FU W Z,et al. A meta-analysis on the effect of ulinastatin on serum levels of C-reactive protein,interleukin 6,and tumor necrosis factor alpha in Asian patients with acute pancreatitis[J]. Genet Test Mol Biomarkers,2016,20(3):118-124.
邓鹏,杨颖,陈冬峨. 乌司他丁治疗急性胰腺炎的系统评价[J]. 公共卫生与预防医学,2010,21(4):22-27.
DENG P,YANG Y,CHEN D E.Ulinastatin for acute pancreatitis:a systematic review[J]. J Public Health Prev Med,2010,21(4):22-27.
刁孟元,何超,单红卫,等. 乌司他丁联合生长抑素治疗重症急性胰腺炎的系统评价[J]. 中国中西医结合急救杂志,2012,19(2):73-78.
DIAO M Y,HE C,SHAN H W,et al. Ulinastatin combined with somatostatin for treatment of severe acute pancreatitis:a systematic review[J]. Chin J Integr Tradit West Med Intensive Crit Care,2012,19(2):73-78.
黄文辉,张云琛,詹志红,等. 乌司他丁与加贝酯分别用于急性胰腺炎和内镜逆行胰胆管造影术后胰腺炎疗效和安全性的荟萃分析[J]. 药学服务与研究,2017,17(4):270-274.
HUANG W H,ZHANG Y C,ZHAN Z H,et al. Comparisons of the efficacy and safety between ulinastatin and gabexate in acute pancreatitis and post-endoscopic retrograde cholangiopancreatography pancreatitis:a meta review[J]. Pharm Care Res,2017,17(4):270-274.
蓝瑞琼,蒋亚斌. 国产乌司他丁治疗急性胰腺炎的系统评价[J]. 中华消化杂志,2005,25(10):618-619.
LAN R Q,JIANG Y B. Systematic review of domestic ulinastatin in the treatment of acute pancreatitis[J]. Chin J Dig,2005,25(10):618-619.
李梁,郑立君. 乌司他丁治疗急性重症胰腺炎的meta分析[J]. 同济大学学报(医学版),2013,34(1):62-68.
LI L,ZHENG L J. Effectiveness of ulinastatin in treatment of severe acute pancreatitis:a meta-analysis[J]. J Tongji Univ Med Sci,2013,34(1):62-68.
马勇,何健强,王韬,等. 乌司他丁治疗重症急性胰腺炎的Meta分析[J]. 中华急诊医学杂志,2018,27(8):912-917.
MA Y,HE J Q,WANG T,et al. The effect of ulinastatin on treatment of severe acute pancreatitis:a meta-analysis[J]. Chin J Emerg Med,2018,27(8):912-917.
王学军,曾宪涛,田钰,等. 国内奥曲肽与乌司他丁联用治疗急性胰腺炎效果的Meta分析[J]. 中国循证医学杂志,2011,11(11):1302-1312.
WANG X J,ZENG X T,TIAN Y,et al. Effectiveness and safety of octreotide combined with ulinastatin for treating acute pancreatitis in China:a meta-analysis[J]. Chin J Evid Based Med,2011,11(11):1302-1312.
王燕慧. 蛋白酶抑制剂治疗急性胰腺炎有效性和安全性的Meta分析[D]. 上海:上海交通大学,2015.
WANG Y H. Meta-analysis of the efficacy and safety of protease inhibitors in the treatment of acute pancreatitis[D]. Shanghai:Shanghai Jiao Tong University,2015.
杨锦林,郭震,吴宗英,等. 乌司他丁治疗急性胰腺炎疗效的系统评价[J]. 中国循证医学杂志,2005,5(4):323-330.
YANG J L,GUO Z,WU Z Y,et al. Ulinastatin for acute pancreatitis:a systematic review[J]. Chin J Evid Based Med,2005,5(4):323-330.
张景春. 乌司他丁对急性胰腺炎临床疗效及安全性的Meta分析[D]. 济南:山东大学,2016.
ZHANG J C. Meta-analysis of clinical efficacy and safety of ulinastatin in the treatment of acute pancreatitis[D]. Jinan:Shandong University,2016.
郭震. 乌司他丁治疗急性胰腺炎疗效的Cochrane系统评价[D]. 成都:四川大学,2003.
GUO Z. Cochrane systematic review of the efficacy of ulinastatin in the treatment of acute pancreatitis[D]. Chengdu:Sichuan University,2003.
郑子恢,高峰,张伟伟,等. 乌司他丁治疗急性胰腺炎有效性的meta分析[J]. 临床药物治疗杂志,2023,21(11):52-59.
ZHENG Z H,GAO F,ZHANG W W,et al. Efficacy of ulinastatin in the treatment of acute pancreatitis:a meta-analysis[J]. Clin Med J,2023,21(11):52-59.
马珂,王贵法. 三种胰酶抑制药治疗急性胰腺炎成本-效果分析[J]. 医药导报,2002,21(11):743-744.
MA K,WANG G F. Cost-effectiveness analysis of three kinds of pancreatin inhibitors in the treatment of acute pancreatitis[J]. Her Med,2002,21(11):743-744.
相延英,吴静芳.乌司他丁治疗急性胰腺炎的费用-效果分析[J]. 临床医药杂志,2003,16(4):41-42.
XIANG Y Y,WU J F. Cost effectiveness analysis of ulastatin in the treatment of acute pancreatitis[J]. Clin Med J,2003,16(4):41-42.
郑继海,王金彩,卢光洲. 乌司他丁与奥曲肽治疗急性胰腺炎的经济学评价[J]. 药学实践杂志,2005,23(2):103-104.
ZHENG J H,WANG J C,LU G Z. Economic evaluation of ulinastatin vs. octreotide in treatment of acute pancreatitis[J]. J Pharm Pract,2005,23(2):103-104.
周蕴,俞伟民. 乌司他丁和施他宁治疗重症急性胰腺炎的成本-效果分析[J]. 海峡药学,2005,17(3):145-147.
ZHOU Y,YU W M. Cost-effectiveness analysis of ulinastatin and Stilamin in the treatment of severe acute pan- creatitis[J]. Strait Pharm J,2005,17(3):145-147.
刘阳,王茜,赵慧颖,等. 乌司他丁在中国健康成年受试者中的耐受性研究[J]. 中国临床药理学杂志,2015,31(21):2111-2113.
LIU Y,WANG Q,ZHAO H Y,et al. Tolerance study of ulinastatin injection in Chinese healthy volunteers[J]. Chin J Clin Pharmacol,2015,31(21):2111-2113.
CHEN Q,HU C Y,LIU Y,et al. Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers:a randomized,double-blind,placebo-controlled,ascending-dose study[J]. PLoS One,2017,12(5):e0177425.
HUANG N,WANG F,WANG Y W,et al. Ulinastatin improves survival of septic mice by suppressing inflammatory response and lymphocyte apoptosis[J]. J Surg Res,2013,182(2):296-302.
CHEN J,WANG J,SU C L,et al. Urinary trypsin inhibitor attenuates LPS-induced endothelial barrier dysfunction by upregulation of vascular endothelial-cadherin expression[J]. Inflamm Res,2016,65(3):213-224.
GALLAGHER J R. Adolescent medical programs:a look at their origin and future[J]. Pediatr Ann,1973,2(6):11-13.
BAE H B,JEONG C W,LI M,et al. Effects of urinary trypsin inhibitor on lipopolysaccharide-induced acute lung injury in rabbits[J]. Inflammation,2012,35(1):176-182.
杨柯君.中国医师协会发布《2013中国急诊急性胰腺炎临床实践指南》[J].上海医药,2014,35(4):42.
YANG K J. The Chinese Medical Association has released the 2013 Clinical Practice Guidelines for Emergency Acute Pancreatitis in China[J]. Shanghai Med Pharm J,2014,35(4):42.
中华医学会急诊分会,京津冀急诊急救联盟,北京医学会急诊分会,等.急性胰腺炎急诊诊断及治疗专家共识[J].中华急诊医学杂志,2021,30(2):161-172.
Emergency Branch of the Chinese Medical Association, Beijing-Tianjin-Hebei Emergency Alliance,Emergency Branch of the Beijing Medical Association,et al. Expert consensus on emergency diagnosis and treatment of acute pancreatitis[J]. Chin J Emerg Med,2021,30(2):161-172.
于学忠,陆一鸣,王仲.急性循环衰竭中国急诊临床实践专家共识[J].中国急救医学,2016,36(1):1-8.
YU X Z,LU Y M,WANG Z. Expert consensus on acute circulatory failure:clinical practice of Chinese emergency physicians[J]. Chin J Emerg Med,2016,36(1):1-8.
陈春雷,陈曹臻,林晖.乌司他丁治疗急性胰腺炎的临床疗效评价[J].中国临床药理学与治疗学,2003(5):570-572.
CHEN C L,CHEN C Z,LIN H. Clinical evaluation on ulinastatin in treatment of patients with acute pancreatitis[J]. Chin J Clin Pharmacol Therapeutics,2003(5):570-572.
0
Views
0
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution